Skip to main content
. 2019 Oct 30;142(12):3806–3833. doi: 10.1093/brain/awz319

Figure 6.

Figure 6

Nanocarrier delivery of a Wnt/β-catenin pathway activator L803mts regulates MG/Mϕ activation in our encephalopathy of prematurity model. (A) Representative images of the in vivo uptake of 3DNA by IBA1+ cells in the subventricular white matter 4 h after intracerebroventricular administration of 3DNA SCR Cy3 (control) or 3DNA L803mts Cy3 (200 ng); scale bar = 40 μm. Bottom right panel shows orthogonal view of white box inset showing co-localization in detail, scale bar = 10 μm. See also Supplementary Figs 4A, B, 5, and Supplementary Video 1. (B) Min to max box and whiskers plots of Nos2, Ptgs2, Tnfa, Il1rn, Socs3 and Il4ra mRNA by qRT-PCR in CD11B+ MG/Mϕ cells from intracerebroventricular injected PBS or IL-1β-treated mice with 3DNA SCR Cy3 or 3DNA L803mt at P1. mRNA levels are presented as a fold-change relative to vehicle group (one-way ANOVA with post hoc Newman-Keuls’s test, ++P < 0.01, +++P < 0.001 for statistically significant difference between the PBS and IL-1β groups also exposed to 3DNA SCR Cy3. *P < 0.05, **P < 0.01 for the effects of 3DNA Wnt modulator delivery, n = 5–6 for PBS groups and n = 9 for IL-1β groups).